|
1
|
Bone H: Future directions in osteoporosis
therapeutics. Endocrinol Metab Clin North Am. 41:655–661. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sharma L, Kapoor D and Issa S:
Epidemiology of osteoarthritis: An update. Curr Opin Rheumatol.
18:147–156. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lane NE: Epidemiology, etiology, and
diagnosis of osteoporosis. Am J Obstet Gynecol. 194(2 Suppl):
S3–S11. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kobayashi Y, Uehara S, Koide M and
Takahashi N: The regulation of osteoclast differentiation by Wnt
signals. Bonekey Rep. 4:7132015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhou H, Wang S, Xue Y and Shi N:
Regulation of the levels of Smad1 and Smad5 in MC3T3-E1 cells by
Icariine in vitro. Mol Med Rep. 9:590–594. 2014.
|
|
6
|
Andújar I, Rios JL, Giner RM and Recio MC:
Pharmacological properties of shikonin-a review of literature since
2002. Planta Med. 79:1685–1697. 2013. View Article : Google Scholar
|
|
7
|
Chen X, Yang L, Oppenheim JJ and Howard
MZ: Cellular pharmacology studies of shikonin derivatives.
Phytother Res. 16:199–209. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang Y, Zhou Y, Jia G, Han B, Liu J, Teng
Y, Lv J, Song Z, Li Y, Ji L, et al: Shikonin suppresses tumor
growth and synergizes with gemcitabine in a pancreatic cancer
xenograft model: Involvement of NF-kB signaling pathway. Biochem
Pharmacol. 88:322–333. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Han W, Li L, Qiu S, Lu Q, Pan Q, Gu Y, Luo
J and Hu X: Shikonin circumvents cancer drug resistance by
induction of a necroptotic death. Mol Cancer Ther. 6:1641–1649.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chang IC, Huang YJ, Chiang TI, Yeh CW and
Hsu LS: Shikonin induces apoptosis through reactive oxygen
species/extracellular signal-regulated kinase pathway in
osteosarcoma cells. Biol Pharm Bull. 33:816–824. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Knoll BI, McCarthy TL, Centrella M and
Shin J: Strain-dependent control of transforming growth factor-beta
function in osteoblasts in an in vitro model: Biochemical events
associated with distraction osteogenesis. Plast Reconstr Surg.
116:224–233. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fagenholz PJ, Warren SM, Greenwald JA,
Bouletreau PJ, Spector JA, Crisera FE and Longaker MT: Osteoblast
gene expression is differentially regulated by TGF-beta isoforms. J
Craniofac Surg. 12:183–190. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cao H, Ke Y, Zhang Y, Zhang CJ, Qian W and
Zhang GL: Icariin stimulates MC3T3-E1 cell proliferation and
differentiation through up-regulation of bone morphogenetic
protein-2. Int J Mol Med. 29:435–439. 2012.
|
|
14
|
Liang W, Lin M, Li X, Li C, Gao B, Gan H,
Yang Z, Lin X, Liao L and Yang M: Icariin promotes bone formation
via the BMP-2/Smad4 signal transduction pathway in the hFOB 1.19
human osteoblastic cell line. Int J Mol Med. 30:889–895.
2012.PubMed/NCBI
|
|
15
|
Cheng H, Jiang W, Phillips FM, Haydon RC,
Peng Y, Zhou L, Luu HH, An N, Breyer B, Vanichakarn P, et al:
Osteogenic activity of the fourteen types of human bone
morphogenetic proteins (BMPs). J Bone Joint Surg Am.
85-A:1544–1552. 2003.PubMed/NCBI
|
|
16
|
Ghosh-Choudhury N, Singha PK, Woodruff K,
St Clair P, Bsoul S, Werner SL and Choudhury GG: Concerted action
of Smad and CREB-binding protein regulates bone morphogenetic
protein-2-stimulated osteoblastic colony-stimulating factor-1
expression. J Biol Chem. 281:20160–20170. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
18
|
Hiligsmann M, Vanoverberghe M, Neuprez A,
Bruyère O and Reginster JY: Cost-effectiveness of strontium
ranelate for the prevention and treatment of osteoporosis. Expert
Rev Pharmacoecon Outcomes Res. 10:359–366. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Compston J: Osteoporosis: Social and
economic impact. Radiol Clin North Am. 48:477–482. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Swarnkar G, Sharan K, Siddiqui JA,
Chakravarti B, Rawat P, Kumar M, Arya KR, Maurya R and
Chattopadhyay N: A novel flavonoid isolated from the steam-bark of
Ulmus Wallichiana Planchon stimulates osteoblast function and
inhibits osteoclast and adipocyte differentiation. Eur J Pharmacol.
658:65–73. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tabuchi M, Miyazawa K, Kimura M, Maeda H,
Kawai T, Kameyama Y and Goto S: Enhancement of crude bone
morphogenetic protein-induced new bone formation and normalization
of endochondral ossification by bisphosphonate treatment in
osteoprotegerin-deficient mice. Calcif Tissue Int. 77:239–249.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen X, Yang L, Zhang N, Turpin JA,
Buckheit RW, Osterling C, Oppenheim JJ and Howard OM: Shikonin, a
component of Chinese herbal medicine, inhibits chemokine receptor
function and suppresses human immunodeficiency virus type 1.
Antimicrob Agents Chemother. 47:2810–2816. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yeh CC, Kuo HM, Li TM, Lin JP, Yu FS, Lu
HF, Chung JG and Yang JS: Shikonin-induced apoptosis involves
caspase-3 activity in a human bladder cancer cell line (T24). In
Vivo. 21:1011–1019. 2007.
|
|
24
|
Wiench B, Eichhorn T, Paulsen M and
Efferth T: Shikonin directly targets mitochondria and causes
mitochondrial dysfunction in cancer cells. Evid Based Complement
Alternat Med. 2012:7260252012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kamiya N, Ye L, Kobayashi T, Mochida Y,
Yamauchi M, Kronenberg HM, Feng JQ and Mishina Y: BMP signaling
negatively regulates bone mass through sclerostin by inhibiting the
canonical Wnt pathway. Development. 135:3801–3811. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yoshida Y, Tanaka S, Umemori H, Minowa O,
Usui M, Ikematsu N, Hosoda E, Imamura T, Kuno J, Yamashita T, et
al: Negative regulation of BMP/Smad signaling by Tob in
osteoblasts. Cell. 103:1085–1097. 2000. View Article : Google Scholar
|
|
27
|
Harada S and Rodan GA: Control of
osteoblast function and regulation of bone mass. Nature.
423:349–355. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang L, Zhang X, Guo Y, Chen X, Li R, Liu
L, Shi C, Guo C and Zhang Y: Involvement of BMPs/Smad signaling
pathway in mechanical response in osteoblasts. Cell Physiol
Biochem. 26:1093–1102. 2010. View Article : Google Scholar
|
